Cantor Fitzgerald Reiterates Neutral Rating for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY - Get Free Report)'s stock had its "neutral" rating reiterated by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $50.00 target price on the biopharmaceutical company's stock. Cantor Fitzgerald's price objective would suggest a potential downside of 6.07% from the company's previous close.

BMY has been the subject of a number of other research reports. Jefferies Financial Group increased their price objective on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a "hold" rating in a research report on Wednesday, August 28th. Sanford C. Bernstein assumed coverage on Bristol-Myers Squibb in a research report on Thursday. They set a "market perform" rating and a $56.00 price target for the company. BMO Capital Markets reaffirmed a "market perform" rating and issued a $48.00 price objective on shares of Bristol-Myers Squibb in a research note on Monday, September 23rd. UBS Group increased their target price on Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a "neutral" rating in a research note on Wednesday, October 9th. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on Bristol-Myers Squibb from $53.00 to $45.00 and set a "hold" rating for the company in a research report on Tuesday, July 23rd. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Bristol-Myers Squibb presently has a consensus rating of "Hold" and a consensus target price of $53.20.

Bristol-Myers Squibb Trading Up 0.1 %

NYSE:BMY traded up $0.05 on Friday, reaching $53.23. The company's stock had a trading volume of 7,184,162 shares, compared to its average volume of 14,752,302. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $57.09. The stock has a 50 day moving average price of $50.36 and a 200 day moving average price of $46.42. The firm has a market cap of $107.90 billion, a price-to-earnings ratio of -17.17, a price-to-earnings-growth ratio of 13.75 and a beta of 0.46. The company has a quick ratio of 1.02, a current ratio of 1.16 and a debt-to-equity ratio of 2.86.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.43. The firm had revenue of $12.20 billion for the quarter, compared to analyst estimates of $11.54 billion. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. Bristol-Myers Squibb's revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.75 EPS. On average, equities analysts anticipate that Bristol-Myers Squibb will post 0.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. ESL Trust Services LLC acquired a new position in Bristol-Myers Squibb in the first quarter valued at approximately $27,000. LGT Financial Advisors LLC grew its position in shares of Bristol-Myers Squibb by 42.7% in the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 227 shares during the last quarter. ORG Wealth Partners LLC purchased a new position in shares of Bristol-Myers Squibb in the 3rd quarter valued at $34,000. MFA Wealth Advisors LLC acquired a new stake in Bristol-Myers Squibb during the 2nd quarter worth $39,000. Finally, Beach Investment Counsel Inc. PA acquired a new position in Bristol-Myers Squibb in the second quarter valued at $42,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.